Which treatment is recommended for RP with RPE65 gene mutation?

Which treatment is recommended for RP with RPE65 gene mutation?

• A. 10,000 IU Vitamin A Palmitate qd, Luxturna if (+) RPE 65 gene, Refer to LV for device evaluation, Refer to OT for mobility training, Refer to PCP for systemic management (hearing loss)
• B. Vitamin C daily
• C. Laser therapy for RP
• D. No treatment for RP

Answer: (A)

For RP caused by RPE65 mutations, the treatment that directly targets the genetic defect is Luxturna, a gene therapy approved for patients with confirmed biallelic RPE65-related retinal dystrophy. This therapy delivers a functional RPE65 gene to the retinal pigment epithelium, helping the visual cycle and improving functional vision, especially in low-light conditions. Because a genetic diagnosis is essential to qualify for Luxturna, treatment planning often includes confirming the mutation first. Vitamin A palmitate at a low-dose daily can be used as an adjunct to slow progression in RP, but it is not a cure and requires monitoring for liver toxicity; its benefit is modest and not specific to all RP cases. In addition to disease-modifying treatment, addressing practical vision needs is important: referrals for low-vision devices and mobility training help patients maximize remaining sight and navigation skills. Since RP can be part of syndromic conditions like Usher syndrome, evaluating and managing associated systemic issues such as hearing loss is also recommended, hence a referral for comprehensive care. The other options don’t offer proven disease modification for this genetic form, and “no treatment” ignores an available, specific therapy and supportive options.

For RP caused by RPE65 mutations, the treatment that directly targets the genetic defect is Luxturna, a gene therapy approved for patients with confirmed biallelic RPE65-related retinal dystrophy. This therapy delivers a functional RPE65 gene to the retinal pigment epithelium, helping the visual cycle and improving functional vision, especially in low-light conditions. Because a genetic diagnosis is essential to qualify for Luxturna, treatment planning often includes confirming the mutation first.

Vitamin A palmitate at a low-dose daily can be used as an adjunct to slow progression in RP, but it is not a cure and requires monitoring for liver toxicity; its benefit is modest and not specific to all RP cases. In addition to disease-modifying treatment, addressing practical vision needs is important: referrals for low-vision devices and mobility training help patients maximize remaining sight and navigation skills.

Since RP can be part of syndromic conditions like Usher syndrome, evaluating and managing associated systemic issues such as hearing loss is also recommended, hence a referral for comprehensive care. The other options don’t offer proven disease modification for this genetic form, and “no treatment” ignores an available, specific therapy and supportive options.